Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.56 Billion EUR | -29.28% |
| 2022 | 2.2 Billion EUR | -13.39% |
| 2021 | 2.54 Billion EUR | -16.33% |
| 2020 | 3.04 Billion EUR | -4.56% |
| 2019 | 3.19 Billion EUR | 1317.53% |
| 2018 | 225.24 Million EUR | -17.88% |
| 2017 | 274.29 Million EUR | -15.51% |
| 2016 | 324.63 Million EUR | 318.81% |
| 2015 | 77.51 Million EUR | 20.49% |
| 2014 | 64.33 Million EUR | -46.5% |
| 2013 | 120.23 Million EUR | 2.87% |
| 2012 | 116.88 Million EUR | 173.86% |
| 2011 | 42.67 Million EUR | -6.11% |
| 2010 | 45.45 Million EUR | 30.49% |
| 2009 | 34.83 Million EUR | 0.96% |
| 2008 | 34.5 Million EUR | -31.13% |
| 2007 | 50.09 Million EUR | -13.78% |
| 2006 | 58.1 Million EUR | 184.45% |
| 2005 | 20.42 Million EUR | 289.38% |
| 2004 | 5.24 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.46 Billion EUR | -6.11% |
| 2024 Q3 | 1.3 Billion EUR | -5.1% |
| 2024 Q2 | 1.38 Billion EUR | -5.89% |
| 2023 Q3 | 1.82 Billion EUR | -5.6% |
| 2023 Q2 | 1.93 Billion EUR | -6.25% |
| 2023 Q1 | 2.06 Billion EUR | -6.37% |
| 2023 FY | 1.56 Billion EUR | -29.28% |
| 2023 Q4 | 1.56 Billion EUR | -14.64% |
| 2022 FY | 2.2 Billion EUR | -13.39% |
| 2022 Q1 | 2.45 Billion EUR | -3.77% |
| 2022 Q2 | 2.39 Billion EUR | -2.47% |
| 2022 Q4 | 2.2 Billion EUR | -3.22% |
| 2022 Q3 | 2.28 Billion EUR | -4.66% |
| 2021 Q1 | 2.91 Billion EUR | -4.39% |
| 2021 Q2 | 2.76 Billion EUR | -5.03% |
| 2021 Q4 | 2.54 Billion EUR | -6.07% |
| 2021 Q3 | 2.71 Billion EUR | -1.9% |
| 2021 FY | 2.54 Billion EUR | -16.33% |
| 2020 Q2 | 3.07 Billion EUR | -2.35% |
| 2020 Q3 | 3 Billion EUR | -2.25% |
| 2020 Q4 | 3.04 Billion EUR | 1.28% |
| 2020 FY | 3.04 Billion EUR | -4.56% |
| 2020 Q1 | 3.15 Billion EUR | -1.27% |
| 2019 Q4 | 3.19 Billion EUR | -3.72% |
| 2019 FY | 3.19 Billion EUR | 1317.53% |
| 2019 Q1 | 224.44 Million EUR | -0.36% |
| 2019 Q3 | 3.31 Billion EUR | 1446.28% |
| 2019 Q2 | 214.48 Million EUR | -4.44% |
| 2018 Q1 | 330.51 Million EUR | 20.5% |
| 2018 Q3 | 297.32 Million EUR | -6.7% |
| 2018 FY | 225.24 Million EUR | -17.88% |
| 2018 Q4 | 225.24 Million EUR | -24.24% |
| 2018 Q2 | 318.68 Million EUR | -3.58% |
| 2017 FY | 274.29 Million EUR | -15.51% |
| 2017 Q4 | 274.29 Million EUR | 77.5% |
| 2017 Q3 | 154.53 Million EUR | -48.37% |
| 2017 Q2 | 299.32 Million EUR | -7.8% |
| 2017 Q1 | 324.66 Million EUR | 0.01% |
| 2016 Q4 | 324.63 Million EUR | -2.88% |
| 2016 FY | 324.63 Million EUR | 318.81% |
| 2016 Q1 | 350.74 Million EUR | 352.48% |
| 2016 Q2 | 336.72 Million EUR | -4.0% |
| 2016 Q3 | 334.27 Million EUR | -0.73% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q2 | 44.8 Million EUR | 0.0% |
| 2015 FY | 77.51 Million EUR | 20.49% |
| 2015 Q4 | 77.51 Million EUR | 83.43% |
| 2015 Q3 | 42.25 Million EUR | -5.69% |
| 2014 Q4 | 64.33 Million EUR | 0.0% |
| 2014 Q2 | 79.96 Million EUR | -0.03% |
| 2014 Q1 | 79.99 Million EUR | -33.47% |
| 2014 FY | 64.33 Million EUR | -46.5% |
| 2013 FY | 120.23 Million EUR | 2.87% |
| 2013 Q3 | 120.23 Million EUR | 11.11% |
| 2013 Q2 | 108.21 Million EUR | 0.0% |
| 2013 Q4 | 120.23 Million EUR | 0.0% |
| 2013 Q1 | 108.21 Million EUR | -7.41% |
| 2012 Q3 | 109.01 Million EUR | -16.78% |
| 2012 Q4 | 116.88 Million EUR | 7.22% |
| 2012 FY | 116.88 Million EUR | 173.86% |
| 2012 Q2 | 130.99 Million EUR | 0.0% |
| 2011 Q2 | 34.69 Million EUR | 0.0% |
| 2011 FY | 42.67 Million EUR | -6.11% |
| 2011 Q4 | 42.67 Million EUR | 0.0% |
| 2010 Q2 | 36.55 Million EUR | 0.0% |
| 2010 FY | 45.45 Million EUR | 30.49% |
| 2010 Q4 | 45.45 Million EUR | 0.0% |
| 2009 Q2 | 26.97 Million EUR | 0.0% |
| 2009 FY | 34.83 Million EUR | 0.96% |
| 2009 Q4 | 34.83 Million EUR | 0.0% |
| 2008 FY | 34.5 Million EUR | -31.13% |
| 2008 Q4 | 34.5 Million EUR | 0.0% |
| 2007 FY | 50.09 Million EUR | -13.78% |
| 2006 FY | 58.1 Million EUR | 184.45% |
| 2005 FY | 20.42 Million EUR | 289.38% |
| 2004 FY | 5.24 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -22495.92% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -1091.764% |
| Adocia SA | 31.87 Million EUR | -4800.628% |
| Aelis Farma SA | 13.08 Million EUR | -11840.596% |
| Biophytis S.A. | 15.84 Million EUR | -9754.439% |
| Advicenne S.A. | 24.37 Million EUR | -6306.982% |
| genOway Société anonyme | 14.45 Million EUR | -10701.401% |
| IntegraGen SA | 5.97 Million EUR | -26018.445% |
| Medesis Pharma S.A. | 6.42 Million EUR | -24204.159% |
| Neovacs S.A. | 3.71 Million EUR | -41973.756% |
| NFL Biosciences SA | 3.62 Million EUR | -43036.336% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -22927.852% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -47083.671% |
| Sensorion SA | 13.22 Million EUR | -11707.653% |
| Theranexus Société Anonyme | 5.01 Million EUR | -31035.789% |
| TME Pharma N.V. | 2.78 Million EUR | -55980.072% |
| Valbiotis SA | 13.7 Million EUR | -11293.566% |
| TheraVet SA | 1.48 Million EUR | -105074.233% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -7530.594% |
| argenx SE | 402.79 Million EUR | -287.745% |
| BioSenic S.A. | 32.26 Million EUR | -4740.782% |
| Celyad Oncology SA | 9.97 Million EUR | -15552.736% |
| DBV Technologies S.A. | 38.74 Million USD | -3931.018% |
| Genfit S.A. | 105.92 Million EUR | -1374.523% |
| GeNeuro SA | 20.13 Million EUR | -7654.904% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -18035.509% |
| Innate Pharma S.A. | 132.29 Million EUR | -1080.593% |
| Inventiva S.A. | 101.59 Million EUR | -1437.34% |
| MaaT Pharma SA | 22.46 Million EUR | -6852.281% |
| MedinCell S.A. | 77.77 Million EUR | -1908.268% |
| Nanobiotix S.A. | 95.74 Million EUR | -1531.324% |
| Onward Medical N.V. | 25.69 Million EUR | -5977.633% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -6116.116% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -2543.63% |
| Oxurion NV | 19.73 Million EUR | -7813.61% |
| Pharming Group N.V. | 228.28 Million EUR | -584.158% |
| Poxel S.A. | 53.9 Million EUR | -2797.59% |
| GenSight Biologics S.A. | 34.72 Million EUR | -4397.452% |
| Transgene SA | 26.51 Million EUR | -5789.92% |
| Financière de Tubize SA | 123.65 Million EUR | -1163.104% |
| UCB SA | 6.56 Billion EUR | 76.206% |
| Valneva SE | 341.14 Million EUR | -357.821% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -34248.581% |